Literature DB >> 28428079

Mineralization-inhibiting effects of transglutaminase-crosslinked polymeric osteopontin.

Betty Hoac1, Valentin Nelea2, Wenge Jiang1, Mari T Kaartinen3, Marc D McKee4.   

Abstract

Osteopontin (OPN) belongs to the SIBLING family (Small, Integrin-Binding LIgand N-linked Glycoproteins) of mineral-binding matrix proteins found in bones and teeth. OPN is a well-known inhibitor of matrix mineralization, and enzymatic modification of OPN can affect this inhibitory function. In bone, OPN exists both as a monomer and as a high-molecular-weight polymer - the latter is formed by transglutaminase-mediated crosslinking of glutamine and lysine residues in OPN to create homotypic protein assemblies. OPN can be covalently crosslinked by transglutaminase 2 (TG2) and Factor XIII-A. Polymeric OPN has increased binding to collagen and promotes osteoblast adhesion, but despite these initial observations, its role in mineralization is not clear. In this study, we investigated the effect of polymerized OPN on mineralization using a hydroxyapatite crystal growth assay and mineralizing MC3T3-E1 osteoblast cultures. In the cultures, endogenous polymeric OPN was detected after mineralization occurred. In cell-free conditions, TG2 was used to crosslink bovine OPN into its polymeric form, and atomic force microscopy and dynamic light scattering revealed variably-sized, large branched aggregates ranging across hundreds of nanometers. These OPN polymers inhibited the growth of hydroxyapatite crystals in solution at concentrations similar to monomeric OPN, although the crosslinking slightly reduced its inhibitory potency. When added to MC3T3-E1 osteoblast cultures, this exogenous polymeric OPN essentially did not inhibit mineralization when given during the later mineralization stages of culture; however, cultures treated early and then continuously with polymeric OPN throughout both the matrix assembly and mineral deposition stages showed reduced mineralization. Immunoblotting of protein extracts from these continuously treated cultures revealed exogenous OPN polymers incorporated into mature matrix that had not yet mineralized. These results suggest that in bone, the increased size and branched structure of crosslinked inhibitory polymeric OPN near the mineralization front could hinder it from accessing focal mineralization sites in the dense collagen-rich matrix, suggesting that OPN-crosslinking into polymers may represent a way to fine-tune the inhibitory potency of OPN on bone mineralization.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone mineralization; Hydroxyapatite; Osteoblasts; Osteopontin; Transglutaminase 2

Mesh:

Substances:

Year:  2017        PMID: 28428079     DOI: 10.1016/j.bone.2017.04.007

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  11 in total

Review 1.  Hypophosphatemic osteosclerosis, hyperostosis, and enthesopathy associated with novel homozygous mutations of DMP1 encoding dentin matrix protein 1 and SPP1 encoding osteopontin: The first digenic SIBLING protein osteopathy?

Authors:  Michael P Whyte; S Deepak Amalnath; William H McAlister; Marc D McKee; Deborah J Veis; Margaret Huskey; Shenghui Duan; Vinieth N Bijanki; Suhas Alur; Steven Mumm
Journal:  Bone       Date:  2019-12-13       Impact factor: 4.398

2.  Proteolytic and nonproteolytic activation mechanisms result in conformationally and functionally different forms of coagulation factor XIII A.

Authors:  Boris A Anokhin; William L Dean; Kerrie A Smith; Matthew J Flick; Robert A S Ariëns; Helen Philippou; Muriel C Maurer
Journal:  FEBS J       Date:  2019-08-28       Impact factor: 5.542

3.  Energy dissipation of osteopontin at a HAp mineral interface: Implications for bone biomechanics.

Authors:  Mahdi Tavakol; Ted J Vaughan
Journal:  Biophys J       Date:  2021-12-18       Impact factor: 4.033

Review 4.  Matrix vesicles from chondrocytes and osteoblasts: Their biogenesis, properties, functions and biomimetic models.

Authors:  Massimo Bottini; Saida Mebarek; Karen L Anderson; Agnieszka Strzelecka-Kiliszek; Lukasz Bozycki; Ana Maria Sper Simão; Maytê Bolean; Pietro Ciancaglini; Joanna Bandorowicz Pikula; Slawomir Pikula; David Magne; Niels Volkmann; Dorit Hanein; José Luis Millán; Rene Buchet
Journal:  Biochim Biophys Acta Gen Subj       Date:  2017-11-03       Impact factor: 3.770

Review 5.  Multiple Pathways for Pathological Calcification in the Human Body.

Authors:  Netta Vidavsky; Jennie A M R Kunitake; Lara A Estroff
Journal:  Adv Healthc Mater       Date:  2020-12-04       Impact factor: 9.933

6.  Chiral Tartaric Acid Improves Fracture Toughness of Bioactive Brushite-Collagen Bone Cements.

Authors:  Stylianos O Sarrigiannidis; Hanan Moussa; Oana Dobre; Matthew J Dalby; Faleh Tamimi; Manuel Salmeron-Sanchez
Journal:  ACS Appl Bio Mater       Date:  2020-07-06

Review 7.  Biocatalysis by Transglutaminases: A Review of Biotechnological Applications.

Authors:  Maria Pia Savoca; Elisa Tonoli; Adeola G Atobatele; Elisabetta A M Verderio
Journal:  Micromachines (Basel)       Date:  2018-10-31       Impact factor: 2.891

8.  Combination of polyetherketoneketone scaffold and human mesenchymal stem cells from temporomandibular joint synovial fluid enhances bone regeneration.

Authors:  Yi Lin; Mayumi Umebayashi; Mohamed-Nur Abdallah; Guoying Dong; Michael G Roskies; Yaoyao Fiona Zhao; Monzur Murshed; Zhiguang Zhang; Simon D Tran
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

9.  Breast cancer-secreted factors perturb murine bone growth in regions prone to metastasis.

Authors:  Aaron E Chiou; Chuang Liu; Inés Moreno-Jiménez; Tengteng Tang; Wolfgang Wagermaier; Mason N Dean; Claudia Fischbach; Peter Fratzl
Journal:  Sci Adv       Date:  2021-03-17       Impact factor: 14.136

10.  Nuclear Transglutaminase 2 interacts with topoisomerase II⍺ to promote DNA damage repair in lung cancer cells.

Authors:  Xiao Lei; Kun Cao; Yuanyuan Chen; Hui Shen; Zhe Liu; Hongran Qin; Jianming Cai; Fu Gao; Yanyong Yang
Journal:  J Exp Clin Cancer Res       Date:  2021-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.